Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 45
Filtrar
1.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 38(3): 99-104, mar. 2020. tab, graf
Artículo en Inglés | IBECS | ID: ibc-200602

RESUMEN

INTRODUCTION: Mycoplasma genitalium is a major cause of urethritis and other genital syndromes. Antibiotic resistance, especially to macrolides, is increasing at an alarming rate worldwide. The aim of this study was to estimate the rate of macrolide resistance in M. genitalium among a 2016-2017 cohort of patients in Barcelona, Spain; and to compare this estimate with previous data from 2013 to 2014 in this region. METHODS: The study was conducted retrospectively with M. genitalium-positive samples collected between December 2016 and February 2017 at the Hospital Vall d'Hebron Microbiology Department. Genotypic markers of macrolide resistance were primarily detected using the ResistancePlus(R) MG molecular assay (SpeeDx). Mutations were then confirmed by sequencing. RESULTS: Macrolide resistance-mediating mutations were detected in 30/83 infections (36.1% [95% CI, 25.9%-47.4%]). This resistance was more frequent among men who have sex with men (55.0% [95% CI, 38.5%-70.7%]) compared to heterosexual men (27.3% [95% CI, 10.7%-50.2%]) and women (9.5% [95% CI, 1.3%-30.4%]), p < 0.001. Additionally, macrolide resistance did not significantly increase in this cohort when compared with previous investigations. CONCLUSION: Despite the current notable rate of macrolide resistance in M. genitalium, resistance did not significantly increase between 2013-2014 and 2016-2017 in our region. Nevertheless, strict local surveillance and the implementation of rapid diagnostic tests that combine the detection of the bacterium and resistance-mediating mutations may facilitate the optimization of antibiotic administration and reduce the transmission of resistance in M. genitalium


INTRODUCCIÓN: Mycoplasma genitalium es causa de uretritis y otras enfermedades genitales. Las resistencias antibióticas, especialmente a macrólidos, están aumentando de forma alarmante a nivel mundial. El objetivo del estudio fue estimar la tasa de resistencia a macrólidos en M. genitalium sobre una cohorte de pacientes entre los años 2016-2017 en Barcelona, España; y comparar esta estimación con datos previos de 2013-2014 en esta región. MÉTODOS: El estudio se realizó de forma retrospectiva sobre muestras positivas para M. genitalium recogidas entre diciembre 2016 y febrero 2017 en el Departamento de Microbiología del Hospital Vall d'Hebron. Los marcadores genotípicos de resistencia a macrólidos se detectaron en primer lugar con el ensayo molecular ResistancePlus(R) MG (SpeeDx). Las mutaciones se confirmaron posteriormente por secuenciación. RESULTADOS: Se detectaron mutaciones asociadas a resistencia a macrólidos en 30/83 (36,1% [IC 95%: 25,9-47,4%]) infecciones. Esta resistencia fue más frecuente en hombres que tienen sexo con hombres (55,0% [IC 95%: 38,5-70,7%]) comparada con la tasa en hombres heterosexuales (27,3% [IC 95%: 10,7-50,2%]) y mujeres (9,5% [IC 95%: 1,3-30,4%]), p < 0,001. Además, la resistencia a macrólidos no aumentó significativamente en esta serie en comparación con investigaciones previas. CONCLUSIÓN: A pesar de la tasa notable de resistencia a macrólidos en M. genitalium, esta no aumentó significativamente entre los años 2013-14 y 2016-17 en nuestro entorno. No obstante, una estricta vigilancia a nivel local junto con la implementación de pruebas diagnósticas rápidas que combinan la detección de la bacteria y las mutaciones de resistencia puede facilitar la optimización de la administración antibiótica y reducir la transmisión de resistencias en M. genitalium


Asunto(s)
Humanos , Femenino , Adolescente , Adulto Joven , Adulto , Persona de Mediana Edad , Farmacorresistencia Bacteriana/genética , Mutación/genética , Macrólidos/farmacología , Mycoplasma genitalium/efectos de los fármacos , Mycoplasma genitalium/genética , Infecciones por Mycoplasma/microbiología , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Estudios Retrospectivos , Estudios de Cohortes , España
2.
Enferm Infecc Microbiol Clin (Engl Ed) ; 38(3): 99-104, 2020 Mar.
Artículo en Inglés, Español | MEDLINE | ID: mdl-31445815

RESUMEN

INTRODUCTION: Mycoplasma genitalium is a major cause of urethritis and other genital syndromes. Antibiotic resistance, especially to macrolides, is increasing at an alarming rate worldwide. The aim of this study was to estimate the rate of macrolide resistance in M. genitalium among a 2016-2017 cohort of patients in Barcelona, Spain; and to compare this estimate with previous data from 2013 to 2014 in this region. METHODS: The study was conducted retrospectively with M. genitalium-positive samples collected between December 2016 and February 2017 at the Hospital Vall d'Hebron Microbiology Department. Genotypic markers of macrolide resistance were primarily detected using the ResistancePlus® MG molecular assay (SpeeDx). Mutations were then confirmed by sequencing. RESULTS: Macrolide resistance-mediating mutations were detected in 30/83 infections (36.1% [95% CI, 25.9%-47.4%]). This resistance was more frequent among men who have sex with men (55.0% [95% CI, 38.5%-70.7%]) compared to heterosexual men (27.3% [95% CI, 10.7%-50.2%]) and women (9.5% [95% CI, 1.3%-30.4%]), p<0.001. Additionally, macrolide resistance did not significantly increase in this cohort when compared with previous investigations. CONCLUSION: Despite the current notable rate of macrolide resistance in M. genitalium, resistance did not significantly increase between 2013-2014 and 2016-2017 in our region. Nevertheless, strict local surveillance and the implementation of rapid diagnostic tests that combine the detection of the bacterium and resistance-mediating mutations may facilitate the optimization of antibiotic administration and reduce the transmission of resistance in M. genitalium.


Asunto(s)
Antibacterianos , Farmacorresistencia Bacteriana , Macrólidos/farmacología , Infecciones por Mycoplasma , Mycoplasma genitalium , Minorías Sexuales y de Género , Antibacterianos/farmacología , Pruebas Diagnósticas de Rutina , Farmacorresistencia Bacteriana/genética , Femenino , Homosexualidad Masculina , Humanos , Masculino , Mutación , Infecciones por Mycoplasma/microbiología , Mycoplasma genitalium/efectos de los fármacos , Mycoplasma genitalium/genética , Estudios Retrospectivos , España
5.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 36(8): 472-477, oct. 2018. tab
Artículo en Inglés | IBECS | ID: ibc-176804

RESUMEN

INTRODUCTION: Streptococcus agalactiae, or group B streptococci (GBS), is the main aetiological agent of early neonatal sepsis in developed countries. This microorganism belongs to the gastrointestinal tract microbiota wherefrom it can colonize the vagina and be vertically transmitted to the child either before or at birth, and subsequently cause infection in the newborn. Approximately, 50% of newborns born to women with GBS become colonized, with 1-2% developing early neonatal infection if no preventive intervention is performed. The aim of this study was to characterize and compare serotypes, virulence factors and antimicrobial resistance of GBS isolates collected from pregnant women and newborns in several hospitals in Catalonia. METHODS: 242 GBS strains were analyzed including 95 colonizers and 68 pathogenic strains isolated from pregnant women, and 79 strains isolated from neonates with sepsis in order to determine serotype, virulence and antimicrobial resistance. RESULTS: Serotype distribution was different among the three groups, with serotypes Ia and II being significantly more frequent among colonizing strains (p = 0.001 and 0.012, respectively). Virulence factors bca and scpB were significantly more frequent among neonatal strains than pathogenic or colonizing strains (p = 0.0001 and 0.002, respectively). Pathogenic strains were significantly more resistant to erythromycin, clindamycin and azithromycin than their non-pathogenic counterparts. CONCLUSIONS: Taking into account that neonatal sepsis represents a significant problem on a global scale, epidemiological surveillance, antimicrobial resistance and GBS virulence at the local level could provide important knowledge about these microorganisms as well as help to improve treatment and prevent invasive infection caused by this microorganism


INTRODUCCIÓN: Streptococcus agalactiae o estreptococos del grupo B (SGB) es el principal agente etiológico de la sepsis neonatal temprana en los países desarrollados. Este microorganismo pertenece a la microbiota del tracto gastrointestinal desde donde puede colonizar la vagina y ser transmitido verticalmente al niño antes o al nacer y posteriormente causar infección en el recién nacido. Aproximadamente el 50% de los recién nacidos de mujeres embarazadas que albergan SGB se colonizan, con 1-2% desarrollando infección neonatal temprana si no se realiza intervención preventiva. El objetivo de este estudio fue caracterizar y comparar serotipos, factores de virulencia y la resistencia a los antimicrobianos de aislamientos de SGB de mujeres embarazadas y neonatos procedentes de varios hospitales de Cataluña. MÉTODOS: Se analizaron 242 cepas de SGB incluyendo 95 colonizadoras y 68 cepas patógenas aisladas de mujeres embarazadas y 79 cepas aisladas de neonatos con sepsis para determinar serotipo, virulencia y resistencia antimicrobiana. RESULTADOS: La distribución de los serotipos fue diferente entre los 3 grupos, siendo los serotipos Ia y II significativamente más frecuentes entre las cepas colonizadoras (p = 0,001 y 0,012, respectivamente). Los factores de virulencia bca y scpB fueron significativamente más frecuentes entre las cepas neonatales que entre las patógenas o colonizadoras (p = 0,0001 y 0,002, respectivamente). Las cepas patógenas fueron significativamente más resistentes a eritromicina, clindamicina y azitromicina que las no patógenas. CONCLUSIONES: Teniendo en cuenta que la sepsis neonatal es un problema importante a nivel mundial, la vigilancia de la epidemiología, la resistencia a los antimicrobianos y la virulencia del SGB a nivel local podría proporcionar un gran conocimiento de estos microorganismos y ayudar a mejorar el tratamiento y la prevención de la infección invasiva causada por este microorganismo


Asunto(s)
Humanos , Femenino , Embarazo , Recién Nacido , Complicaciones Infecciosas del Embarazo/microbiología , Streptococcus agalactiae/patogenicidad , Streptococcus agalactiae , Enfermedades del Recién Nacido/microbiología , Antibacterianos/farmacología , Virulencia/genética , Farmacorresistencia Bacteriana/genética , Serotipificación
6.
Enferm Infecc Microbiol Clin (Engl Ed) ; 36(8): 472-477, 2018 Oct.
Artículo en Inglés, Español | MEDLINE | ID: mdl-29029763

RESUMEN

INTRODUCTION: Streptococcus agalactiae, or group B streptococci (GBS), is the main aetiological agent of early neonatal sepsis in developed countries. This microorganism belongs to the gastrointestinal tract microbiota wherefrom it can colonize the vagina and be vertically transmitted to the child either before or at birth, and subsequently cause infection in the newborn. Approximately, 50% of newborns born to women with GBS become colonized, with 1-2% developing early neonatal infection if no preventive intervention is performed. The aim of this study was to characterize and compare serotypes, virulence factors and antimicrobial resistance of GBS isolates collected from pregnant women and newborns in several hospitals in Catalonia. METHODS: 242 GBS strains were analyzed including 95 colonizers and 68 pathogenic strains isolated from pregnant women, and 79 strains isolated from neonates with sepsis in order to determine serotype, virulence and antimicrobial resistance. RESULTS: Serotype distribution was different among the three groups, with serotypes Ia and II being significantly more frequent among colonizing strains (p=0.001 and 0.012, respectively). Virulence factors bca and scpB were significantly more frequent among neonatal strains than pathogenic or colonizing strains (p=0.0001 and 0.002, respectively). Pathogenic strains were significantly more resistant to erythromycin, clindamycin and azithromycin than their non-pathogenic counterparts. CONCLUSIONS: Taking into account that neonatal sepsis represents a significant problem on a global scale, epidemiological surveillance, antimicrobial resistance and GBS virulence at the local level could provide important knowledge about these microorganisms as well as help to improve treatment and prevent invasive infection caused by this microorganism.


Asunto(s)
Macrólidos/farmacología , Streptococcus agalactiae/efectos de los fármacos , Streptococcus agalactiae/patogenicidad , Farmacorresistencia Bacteriana , Femenino , Humanos , Recién Nacido , Embarazo , Serogrupo , España , Streptococcus agalactiae/clasificación , Streptococcus agalactiae/aislamiento & purificación , Virulencia
7.
Artículo en Inglés | MEDLINE | ID: mdl-28971876

RESUMEN

The aim of the current study was to compare community-acquired acute pyelonephritis (CA-APN) with health care-associated acute pyelonephritis (HCA-APN), describe the outcomes, and identify variables that could predict antimicrobial susceptibility. We conducted an observational study that included all consecutive episodes of acute pyelonephritis (APN) in adults during 2014 at a Spanish university hospital. From each episode, demographic data, comorbidities, clinical presentation, microbiological data, antimicrobial therapy, and outcome were recorded. A multivariable logistic regression model was performed to define the variables associated with antimicrobial resistance. A total of 607 patients, 503 (82.9%) with CA-APN and 104 (17.1%) with HCA-APN, were included in the study. Patients with HCA-APN were older than patients with CA-APN (70.4 versus 50.6 years; P < 0.001) and had higher rates of previous urinary tract infections (UTIs) (56.5% versus 24.5%; P < 0.001) and previous antibiotic use (56.8% versus 22.8%; P < 0.001). Escherichia coli was more frequently isolated from patients with CA-APN than from patients with HCA-APN (79.9% versus 50.5%; P < 0.001). The rates of resistance of Escherichia coli strains from CA-APN patients versus HCA-APN patients were as follows: amoxicillin-clavulanic acid, 22.4% versus 53.2% (P = 0.001); cefuroxime, 7.7% versus 43.5% (P = 0.001); cefotaxime, 4.3% versus 32.6% (P < 0.001); ciprofloxacin, 22.8% versus 74.5% (P < 0.001); and co-trimoxazole, 34.5% versus 58.7% (P = 0.003). The site of acquisition, recurrent UTIs, and previous antibiotic use were independent risk factors for antimicrobial resistance. Relapse rates were significantly higher when definitive antimicrobial treatment was not adequate (37.1% versus 9.3% when definitive antimicrobial treatment was adequate; P < 0.001). Our study reflects the rise of resistance to commonly used antibiotics in acute pyelonephritis. In order to choose the adequate empirical antibiotic therapy, risk factors for resistance should be considered.


Asunto(s)
Antibacterianos/uso terapéutico , Infección Hospitalaria/tratamiento farmacológico , Farmacorresistencia Bacteriana , Infecciones por Escherichia coli/tratamiento farmacológico , Escherichia coli/efectos de los fármacos , Pielonefritis/tratamiento farmacológico , Infecciones Urinarias/tratamiento farmacológico , Enfermedad Aguda , Adulto , Anciano , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Cefotaxima/uso terapéutico , Cefuroxima/uso terapéutico , Ciprofloxacina/uso terapéutico , Estudios de Cohortes , Infecciones Comunitarias Adquiridas , Infección Hospitalaria/microbiología , Infección Hospitalaria/patología , Investigación Empírica , Escherichia coli/crecimiento & desarrollo , Infecciones por Escherichia coli/microbiología , Infecciones por Escherichia coli/patología , Femenino , Hospitales Universitarios , Humanos , Modelos Logísticos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Pielonefritis/microbiología , Pielonefritis/patología , Factores de Riesgo , España , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico , Infecciones Urinarias/microbiología , Infecciones Urinarias/patología
8.
Eur J Pediatr ; 176(9): 1227-1234, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28770413

RESUMEN

Escherichia coli early-onset sepsis (EOS) is an important cause of mortality and morbidity in neonates, especially in preterm and very low birth weight (VLBW) newborns. The aim of our study was to evaluate potential changes in the clinical and microbiological characteristics of E. coli EOS in our setting. Epidemiological, clinical, and microbiological data from all neonates with proven E. coli EOS from January 1994 to December 2014 were retrospectively collected in a single tertiary care hospital in Barcelona (Spain). Seventy-eight E. coli EOS cases were analyzed. A slight increase in the incidence of E. coli EOS was observed during the study period. VLBW newborns remained the group with higher incidence (10.4 cases per 1000 live births) and mortality (35.3%). Systematic use of PCR increased E. coli EOS diagnosis, mainly in the term newborn group. There was an increase in resistant E. coli strains causing EOS, with especially high resistance to ampicillin and gentamicin (92.8 and 28.6%, respectively). Nonetheless, resistant strains were not associated with poorer clinical outcomes. CONCLUSIONS: There is an urgent need to reconsider the empirical therapy used in neonatal EOS, particularly in VLBW newborns. What is Known: • E. coli early-onset sepsis (EOS) and E. coli resistant strains have been described as overall stable but increasing in VLBW neonates (< 1.500 g) in previous studies. What is New: • Our study shows an increasing incidence of E. coli EOS in all age groups, overruling group B Streptoccocus for the last 10 years. E. coli resistant strains also increased equally in all age groups, with high resistance rates to our first line antibiotics (ampicillin and gentamicin). • Empiric antibiotic therapy of EOS, mainly in VLBW newborns, should be adapted to this new scenario.


Asunto(s)
Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana , Infecciones por Escherichia coli/tratamiento farmacológico , Escherichia coli/efectos de los fármacos , Sepsis Neonatal/tratamiento farmacológico , Sepsis Neonatal/epidemiología , Adolescente , Adulto , Escherichia coli/aislamiento & purificación , Infecciones por Escherichia coli/sangre , Infecciones por Escherichia coli/epidemiología , Femenino , Edad Gestacional , Humanos , Incidencia , Recien Nacido con Peso al Nacer Extremadamente Bajo , Recién Nacido , Recien Nacido Prematuro , Masculino , Sepsis Neonatal/sangre , Reacción en Cadena de la Polimerasa , Estudios Retrospectivos , España/epidemiología , Adulto Joven
9.
Sex Transm Dis ; 44(8): 457-462, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28703723

RESUMEN

BACKGROUND: Macrolide and fluoroquinolone resistance is alarmingly emerging in M. genitalium worldwide. This article provides the first estimates of the current prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Barcelona, Spain, and identifies risk factors associated with the acquisition of these resistances. METHODS: The study was conducted retrospectively with specimens submitted between February 2013 and March 2014 to the microbiology department of the Vall d'Hebron Hospital, Barcelona, where M. genitalium was detected using nucleic acid amplification methods. DNA sequencing of 23S ribosomal RNA gene and parC was performed in the Statens Serum Institut, Copenhagen, to detect genotypic macrolide and fluoroquinolone resistance markers, respectively. RESULTS: Macrolide resistance-mediating mutations were detected in 35% (95% confidence interval, 24%-47%) of the M. genitalium-positive episodes, whereas 8% (95% confidence interval, 3%-17%) carried fluoroquinolone resistance mutations. Of them, three cases harbored multidrug resistance to both classes of antibiotics. Men who had sex with men (P = 0.002) and treatment with azithromycin within the previous 12 months (P = 0.006) were strongly associated with macrolide resistance. CONCLUSION: The widespread appearance of resistances, also in Spain, makes imperative the implementation of combined diagnostic-resistance detection assays for M. genitalium to facilitate the optimization of antibiotic treatment in the management of nongonococcal urethritis and potentially reduce the transmission of resistances.


Asunto(s)
Antibacterianos/farmacología , Fluoroquinolonas/farmacología , Macrólidos/farmacología , Infecciones por Mycoplasma/microbiología , Mycoplasma genitalium/efectos de los fármacos , Uretritis/microbiología , Adolescente , Adulto , Azitromicina/uso terapéutico , Estudios de Cohortes , Farmacorresistencia Bacteriana , Femenino , Genotipo , Homosexualidad Masculina , Humanos , Masculino , Persona de Mediana Edad , Mutación , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/epidemiología , Mycoplasma genitalium/genética , Estudios Retrospectivos , España/epidemiología , Uretritis/tratamiento farmacológico , Uretritis/epidemiología , Adulto Joven
10.
Antimicrob Agents Chemother ; 60(3): 1854-8, 2015 Dec 14.
Artículo en Inglés | MEDLINE | ID: mdl-26666924

RESUMEN

This is a retrospective study of 15 difficult-to-treat (i.e., exhibiting previous failure, patient side effects, or resistance to ciprofloxacin and co-trimoxazole) chronic bacterial prostatitis infections (5 patients with multidrug-resistant Enterobacteriaceae [MDRE]) receiving fosfomycin-tromethamine at a dose of 3 g per 48 to 72 h for 6 weeks. After a median follow-up of 20 months, 7 patients (47%) had a clinical response, and 8 patients (53%) had persistent microbiological eradication; 4/5 patients with MDRE isolates achieved eradication. There were no side effects. Fosfomycin-tromethamine is a possible alternative therapy for chronic bacterial prostatitis.


Asunto(s)
Antibacterianos/uso terapéutico , Ciprofloxacina/uso terapéutico , Farmacorresistencia Bacteriana Múltiple , Fosfomicina/uso terapéutico , Prostatitis/tratamiento farmacológico , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Prostatitis/microbiología , Estudios Retrospectivos , Trometamina , Adulto Joven
11.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 33(7): 446-450, ago.-sept. 2015. tab, graf
Artículo en Español | IBECS | ID: ibc-140507

RESUMEN

OBJETIVOS: Estudiar la evolución de la incidencia de sepsis neonatal precoz (SNP) por Streptococcus agalactiae en el área de Barcelona y analizar los fallos de cumplimiento del protocolo de prevención. MÉTODOS: Se revisaron retrospectivamente todas las SNP en 8 centros sanitarios del área de Barcelona durante 2004-2010. RESULTADOS: Se diagnosticaron 49 SNP (48 gestantes). La incidencia fue de 0,29‰ recién nacidos vivos (0,18-0,47‰), presentando oscilaciones sin diferencias significativas a lo largo de los 7 años de estudio. La mortalidad fue del 8,16%. En el 68,5% los estudios de colonización maternos fueron negativos y en el 21% no se realizaron. El 58,3% de las gestantes no presentaron ningún factor de riesgo y el 22,9% de los partos fueron prematuros. El 58% de las gestantes no recibieron profilaxis antibiótica intraparto por no estar indicada según protocolo, y el 42%, por fallo de cumplimiento (3 cepas fueron resistentes a eritromicina). La resistencia a clindamicina fue del 33,3%. Los serotipos de Streptococcus agalactiae más frecuentes fueron el III, el V y el ia. CONCLUSIONES: No se han producido cambios significativos en la incidencia de SNP por Streptococcus agalactiae en los 7 años del estudio. El aumento de la sensibilidad de los métodos de cribado, las técnicas moleculares intraparto, la realización del antibiograma de las cepas de gestantes y la mayor comunicación entre los centros sanitarios pueden contribuir a una mejor aplicación del protocolo y a una reducción de la incidencia de SNP


OBJECTIVES: To study the evolution of the incidence of early-onset neonatal sepsis (EOS) by Streptococcus agalactiae in the area of Barcelona and to analyze failure of compliance with the prevention protocol. METHODS: A retrospective review was carried out on EOS cases in 8 Health-Care Centers in the Barcelona area between 2004 and 2010. RESULTS: Forty-nine newborns from 48 mothers were diagnosed with EOS. The incidence was 0.29‰ living newborns (0.18-0.47‰), with no significant differences in the fluctuations along the 7 years. The mortality rate was 8.16%. In 68.5% cases the maternal colonization studies were negative, and in 21% these studies were not performed. No risk factors were detected in 58.3% of pregnant women, and 22.9% of births were premature. In 58% of cases intra-partum antibiotic prophylaxis was not administered because it was not indicated, and in 42% due to failure to follow the protocol (3 strains were resistant to erythromycin). Resistance to clindamycin was 33.3%. The Streptococcus agalactiae serotypes more frequently isolated were III, V, and ia. CONCLUSIONS: No significant changes were detected in the incidence of Streptococcus agalactiae EOS in the 7 years of the study. The increased sensitivity of screening methods with the use of molecular techniques, the performance of susceptibility testing of strains isolated from pregnant women, and the improvement of communication between Health-Care Centers, can contribute to a better implementation of the protocol, as well as to reduce the incidence of EOS


Asunto(s)
Femenino , Humanos , Recién Nacido , Masculino , Sepsis/epidemiología , Sepsis/microbiología , Diagnóstico Precoz , Streptococcus agalactiae/aislamiento & purificación , Clindamicina , Profilaxis Pre-Exposición/métodos , Protocolos Clínicos , Estudios Retrospectivos , Profilaxis Antibiótica , Indicadores de Morbimortalidad
12.
Enferm Infecc Microbiol Clin ; 33(7): 446-50, 2015.
Artículo en Español | MEDLINE | ID: mdl-25541009

RESUMEN

OBJECTIVES: To study the evolution of the incidence of early-onset neonatal sepsis (EOS) by Streptococcus agalactiae in the area of Barcelona and to analyze failure of compliance with the prevention protocol. METHODS: A retrospective review was carried out on EOS cases in 8 Health-Care Centers in the Barcelona area between 2004 and 2010. RESULTS: Forty-nine newborns from 48 mothers were diagnosed with EOS. The incidence was 0.29‰ living newborns (0.18-0.47‰), with no significant differences in the fluctuations along the 7 years. The mortality rate was 8.16%. In 68.5% cases the maternal colonization studies were negative, and in 21% these studies were not performed. No risk factors were detected in 58.3% of pregnant women, and 22.9% of births were premature. In 58% of cases intra-partum antibiotic prophylaxis was not administered because it was not indicated, and in 42% due to failure to follow the protocol (3 strains were resistant to erythromycin). Resistance to clindamycin was 33.3%. The Streptococcus agalactiae serotypes more frequently isolated were iii, v, and ia. CONCLUSIONS: No significant changes were detected in the incidence of Streptococcus agalactiae EOS in the 7 years of the study. The increased sensitivity of screening methods with the use of molecular techniques, the performance of susceptibility testing of strains isolated from pregnant women, and the improvement of communication between Health-Care Centers, can contribute to a better implementation of the protocol, as well as to reduce the incidence of EOS.


Asunto(s)
Sepsis Neonatal/epidemiología , Infecciones Estreptocócicas/epidemiología , Streptococcus agalactiae/aislamiento & purificación , Edad de Inicio , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Profilaxis Antibiótica/estadística & datos numéricos , Cesárea/estadística & datos numéricos , Diagnóstico Tardío , Parto Obstétrico , Reacciones Falso Negativas , Femenino , Humanos , Incidencia , Recién Nacido , Sepsis Neonatal/tratamiento farmacológico , Sepsis Neonatal/microbiología , Sepsis Neonatal/prevención & control , Embarazo , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Complicaciones Infecciosas del Embarazo/epidemiología , Estudios Retrospectivos , Factores de Riesgo , España/epidemiología , Infecciones Estreptocócicas/tratamiento farmacológico , Infecciones Estreptocócicas/microbiología , Infecciones Estreptocócicas/prevención & control , Población Urbana
13.
J Antimicrob Chemother ; 67(8): 1858-60, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22566592

RESUMEN

OBJECTIVES: The aim of this study was to characterize the first two extended-spectrum cephalosporin-resistant and multidrug-resistant (MDR) Neisseria gonorrhoeae isolates collected from two sexually related patients (men who have sex with men) in Spain. METHODS: Antimicrobial susceptibility was studied by Etest. Genes involved in quinolone, ceftriaxone and multidrug resistance were amplified by PCR and sequenced in both directions. The isolates were typed by N. gonorrhoeae multi-antigen sequence typing (NG-MAST). RESULTS: The two isolates had the same MDR profile, showing resistance to penicillin (MIC 0.094 mg/L; ß-lactamase negative), ceftriaxone (MIC 1.5 mg/L), cefixime (MIC 1.5 mg/L), cefotaxime (MIC 1 mg/L), ciprofloxacin (MIC >32 mg/L) and tetracycline (MIC 1.5 mg/L). NG-MAST showed that both isolates belonged to sequence type (ST) 1407 (porB-908 and tbpB-110). Ciprofloxacin resistance was due to amino acid substitutions in GyrA (S91F and D95G) and ParC (S87R). An A deletion in the promoter of the MtrCDE efflux pump (mtrR) was detected. No changes were detected in the pilQ gene. The outer membrane protein PorB showed two substitutions at G120K and A121N. An L421P substitution was observed in the PBP1A (ponA) sequence. The sequence of PBP2 (penA) showed a mosaic structure related to genotype XXXIV with a single additional amino acid substitution (A501P). This genotype was identical to a recently described French isolate (F89). CONCLUSIONS: This is the first reported case of high-level extended-spectrum cephalosporin-resistant N. gonorrhoeae transmission. The molecular typing and MDR genotype suggest possible European spread of this strain, highlighting the need for surveillance and the importance of testing the susceptibility of N. gonorrhoeae to extended-spectrum cephalosporins.


Asunto(s)
Antibacterianos/farmacología , Ceftriaxona/farmacología , Gonorrea/epidemiología , Neisseria gonorrhoeae/clasificación , Neisseria gonorrhoeae/genética , Resistencia betalactámica , ADN Bacteriano/química , ADN Bacteriano/genética , Genotipo , Gonorrea/microbiología , Homosexualidad Masculina , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Epidemiología Molecular , Tipificación Molecular , Neisseria gonorrhoeae/efectos de los fármacos , Neisseria gonorrhoeae/aislamiento & purificación , Reacción en Cadena de la Polimerasa , Análisis de Secuencia de ADN , España/epidemiología
14.
Enferm Infecc Microbiol Clin ; 29(1): 52-7, 2011 Jan.
Artículo en Español | MEDLINE | ID: mdl-21310512

RESUMEN

For the diagnosis of urinary tract infection (UTI), besides the quantification of bacteria in the urine, cellular elements contained in the urine, the collection method used and the clinical syndrome should also be considered. Therefore, the microbiological diagnosis of UTI should be performed by an experienced person who takes into account the diversity of situations that may influence the result of each of the cultures. The processing of urine samples depends on the number of samples received daily. In laboratories with a high number, it is impossible to culture each of them, so negative urines have to be ruled out by using automated systems and cultivate only those that are positive. This review includes an analysis of the methods currently available for this screening. It also includes procedures to be performed in special situations such as prostatitis, UTI caused by fastidious microorganisms and other kind of infections that may be diagnosed in a urine test.


Asunto(s)
Infecciones Urinarias/diagnóstico , Infecciones Urinarias/microbiología , Técnicas Bacteriológicas , Humanos , Manejo de Especímenes
15.
Artículo en Español | IBECS | ID: ibc-97335

RESUMEN

Para el diagnóstico de la infección urinaria (IU), además del recuento de bacterias en orina, debe tenerse en cuenta los elementos formes contenidos en la misma, el tipo de entidad clínica y el método de recogida empleado. Por ello, el diagnóstico microbiológico de la IU debe ser realizado por una persona experta que tenga en cuenta la diversidad de situaciones que traduce cada uno de los urocultivos que interpreta. El procesamiento de las muestras de orina depende del numero de muestras recibidas diariamente. En laboratorios con un alto número es imposible el cultivo de cada una de ellas, por lo que se impone descartar las orinas negativas mediante sistemas automatizados y cultivar sólo aquellas positivas. La presente revisión incluye un análisis de los métodos disponibles actualmente para hacer este cribado. Incluye también procedimientos a realizar en situaciones especiales como prostatitis, IU por microorganismos fastidiosos e infecciones que se diagnostican con el examen de la orina (AU)


For the diagnosis of urinary tract infection (UTI), besides the quantification of bacteria in the urine, cellular elements contained in the urine, the collection method used and the clinical syndrome should also be considered. Therefore, the microbiological diagnosis of UTI should be performed by an experienced person who takes into account the diversity of situations that may influence the result of each of the cultures. The processing of urine samples depends on the number of samples received daily. In laboratories with a high number, it is impossible to culture each of them, so negative urines have to be ruled out by using automated systems and cultivate only those that are positive. This review includes an analysis of the methods currently available for this screening. It also includes procedures to be performed in special situations such as prostatitis, UTI caused by fastidious microorganisms and other kind of infections that may be diagnosed in a urine test (AU)


Asunto(s)
Humanos , Infecciones Urinarias/microbiología , Técnicas Microbiológicas/métodos , Manejo de Especímenes/métodos , Nitrato-Reductasa/análisis
16.
Enferm Infecc Microbiol Clin ; 28 Suppl 3: 63-8, 2010 Oct.
Artículo en Español | MEDLINE | ID: mdl-21129589

RESUMEN

This article aims to reflect on which areas or tasks of microbiology laboratories could be unified with those of clinical biochemistry, hematology, immunology or pathology laboratories to benefit patients and the health system, as well as the areas that should remain independent since their amalgamation would not only fail to provide a benefit but could even jeopardize the quality of microbiological diagnosis, and consequently patient care. To do this, the distinct analytic phases of diagnosis are analyzed, and the advantages and disadvantages of amalgamation are evaluated in each phase. The pros and cons of the unification of certain areas such as the computer system, occupational risk units, customer service, purchasing logistics, and materials storage, etc, are also discussed. Lastly, the effect of unification on urgent microbiology diagnosis is analyzed. Microbiological diagnosis should be unique. The microbiologist should perform an overall evaluation of the distinct techniques used for a particular patient, both those that involve direct diagnosis (staining, culture, antigen detection techniques or molecular techniques) and indirect diagnosis (antibody detection). Moreover, the microbiology laboratory should be independent, with highly trained technicians and specialists in microbiology that provide added value as experts in infection and as key figures in the process of establishing a correct etiological diagnosis.


Asunto(s)
Laboratorios/organización & administración , Microbiología , Laboratorios/normas
17.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 28(supl.3): 63-68, oct. 2010.
Artículo en Español | IBECS | ID: ibc-179501

RESUMEN

Este trabajo pretende ser una reflexión de las autoras sobre qué áreas o tareas del laboratorio de microbiología podrían unificarse con las de los laboratorios de bioquímica clínica, hematología, inmunología y anatomía patológica con el objetivo de obtener un beneficio para el paciente y el sistema sanitario, así como las áreas que deberían conservar su independencia, ya que su unificación no sólo no aportaría ningún beneficio, sino que, incluso, pondría en peligro la calidad del diagnóstico microbiológico y, consecuentemente, la atención médica prestada al paciente. Para ello, se hace un análisis de las distintas fases analíticas del diagnóstico, ponderando las ventajas e inconvenientes de la unificación en cada una de ellas. Se valoran también pros y contras de la unificación sobre áreas transversales, como el sistema informático, las unidades de riesgos laborales y de atención al cliente, la logística de compras, el almacenamiento de material, etc. Por último, se analiza el efecto de la unificación con respecto a la atención urgente en microbiología. El diagnóstico microbiológico debe ser único. El microbiólogo debe valorar conjuntamente los resultados de las diferentes técnicas que se han aplicado a un paciente, tanto las que suponen un diagnóstico directo (tinción, cultivo, técnicas de detección de antígenos o técnicas moleculares) como indirecto (detección de anticuerpos). Además, el laboratorio de microbiología ha de ser independiente, con técnicos entrenados y con facultativos especialistas en microbiología que aportan valor añadido como expertos en la infección y que son claves en el proceso de establecer un diagnóstico etiológico preciso


This article aims to reflect on which areas or tasks of microbiology laboratories could be unified with those of clinical biochemistry, hematology, immunology or pathology laboratories to benefit patients and the health system, as well as the areas that should remain independent since their amalgamation would not only fail to provide a benefit but could even jeopardize the quality of microbiological diagnosis, and consequently patient care. To do this, the distinct analytic phases of diagnosis are analyzed, and the advantages and disadvantages of amalgamation are evaluated in each phase. The pros and cons of the unification of certain areas such as the computer system, occupational risk units, customer service, purchasing logistics, and materials storage, etc, are also discussed. Lastly, the effect of unification on urgent microbiology diagnosis is analyzed. Microbiological diagnosis should be unique. The microbiologist should perform an overall evaluation of the distinct techniques used for a particular patient, both those that involve direct diagnosis (staining, culture, antigen detection techniques or molecular techniques) and indirect diagnosis (antibody detection). Moreover, the microbiology laboratory should be independent, with highly trained technicians and specialists in microbiology that provide added value as experts in infection and as key figures in the process of establishing a correct etiological diagnosis


Asunto(s)
Laboratorios/organización & administración , Microbiología , Automatización de Laboratorios/normas , Laboratorios/normas
18.
Int J Antimicrob Agents ; 36(1): 73-8, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20392607

RESUMEN

The localisation and genetic organisation of bla(CTX-M-15) were studied in 37 CTX-M-15-producing Klebsiella pneumoniae isolates collected from 2005 to 2008 within the Barcelona metropolitan area. Polymerase chain reaction (PCR)-based replicon typing and Southern hybridisations were used to identify the bla(CTX-M-15) location. The genetic environment was analysed by PCR mapping and sequencing, and transferability of bla(CTX-M-15) was evaluated by conjugation and transformation assays. The majority of the 37 isolates carried bla(CTX-M-15) in a plasmid location, frequently associated with the aac(6')-Ib-cr gene. Plasmids encoding bla(CTX-M-15) carried three distinct replicons, i.e. IncFII, IncR and IncFIIk, the latter two not having been described previously in association with bla(CTX-M-15). Several of these plasmids were not self-transferable. Furthermore, in all isolates belonging to sequence type ST-1, bla(CTX-M-15) was found integrated into the K. pneumoniae chromosome. In all the studied isolates, the mobile element ISEcp1 was found upstream of bla(CTX-M-15), whereas IS26 was found inserted within ISEcp1 in several isolates, in previously unreported positions. In conclusion, these findings indicate that among K. pneumoniae strains isolated in the Barcelona metropolitan area, bla(CTX-M-15) is associated with diverse genetic elements, including the IncR and IncFIIk replicons, as reported for the first time here, and the chromosome.


Asunto(s)
Proteínas Bacterianas/genética , Cromosomas Bacterianos , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/enzimología , Plásmidos , beta-Lactamasas/genética , Southern Blotting , ADN Bacteriano/química , ADN Bacteriano/genética , Orden Génico , Genes Bacterianos , Humanos , Klebsiella pneumoniae/aislamiento & purificación , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa , Recombinación Genética , Análisis de Secuencia de ADN , España
19.
Appl Environ Microbiol ; 76(9): 2799-805, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20228098

RESUMEN

To ascertain whether on animal farms there reside extended-spectrum beta-lactamase (ESBL) and plasmidic class C beta-lactamase-producing Escherichia coli isolates potentially pathogenic for humans, phylogenetic analyses, pulsed-field gel electrophoresis (PFGE) typing, serotyping, and virulence genotyping were performed for 86 isolates from poultry (57 isolates) and pig (29 isolates) farms. E. coli isolates from poultry farms carried genes encoding enzymes of the CTX-M-9 group as well as CMY-2, whereas those from pig farms mainly carried genes encoding CTX-M-1 enzymes. Poultry and pig isolates differed significantly in their phylogenetic group assignments, with phylogroup A predominating in pig isolates and phylogroup D predominating in avian isolates. Among the 86 farm isolates, 23 (26.7%) carried two or more virulence genes typical of extraintestinal pathogenic E. coli (ExPEC). Of these, 20 were isolated from poultry farms and only 3 from pig farms. Ten of the 23 isolates belonged to the classic human ExPEC serotypes O2:H6, O2:HNM, O2:H7, O15:H1, and O25:H4. Despite the high diversity of serotypes and pulsotypes detected among the 86 farm isolates, 13 PFGE clusters were identified. Four of these clusters contained isolates with two or more virulence genes, and two clusters exhibited the classic human ExPEC serotypes O2:HNM (ST10) and O2:H6 (ST115). Although O2:HNM and O2:H6 isolates of human and animal origins differed with respect to their virulence genes and PFGE pulsotypes, the O2:HNM isolates from pigs showed the same sequence type (ST10) as those from humans. The single avian O15:H1 isolate was compared with human clinical isolates of this serotype. Although all were found to belong to phylogroup D and shared the same virulence gene profile, they differed in their sequence types (ST362-avian and ST393-human) and PFGE pulsotypes. Noteworthy was the detection, for the first time, in poultry farms of the clonal groups O25b:H4-ST131-B2, producing CTX-M-9, and O25a-ST648-D, producing CTX-M-32. The virulence genes and PFGE profiles of these two groups were very similar to those of clinical human isolates. While further studies are required to determine the true zoonotic potential of these clonal groups, our results emphasize the zoonotic risk posed especially by poultry farms, but also by pig farms, as reservoirs of ESBL- and CMY-2-encoding E. coli.


Asunto(s)
Escherichia coli/clasificación , Agricultura , Animales , Pollos , Farmacorresistencia Bacteriana , Electroforesis en Gel de Campo Pulsado , Escherichia coli/genética , Escherichia coli/aislamiento & purificación , Infecciones por Escherichia coli/microbiología , Humanos , Serotipificación , España , Sus scrofa , beta-Lactamasas/genética
20.
Res Microbiol ; 160(8): 585-91, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19723578

RESUMEN

The aim of this study was to assess the prevalence of antibiotic-resistant stx(2) gene-carrying Escherichia coli isolated from human and animal wastewater with regard to their animal/human origin, serotype, phylogenetic background and virulence factors. The isolates were characterized by PCR in relation to stx variant, phylogenetic group and other virulence genes (stx(1), ehxA and saa). Antibiotic resistance was found in 92% of the stx(2) gene-carrying E. coli strains, with 77% showing intermediate resistance or full resistance to more than one antibiotic. High levels of resistance were observed to chloramphenicol, tetracycline, sulfamethoxazole, streptomycin, trimethoprim, and trimethoprim + sulfamethoxazole, with resistance values of 79%, 69%, 63%, 58%, 47% and 42%, respectively, and a higher prevalence among those strains isolated from animal wastewater. There was no association between the E. coli serotype and/or phylogroup and the antimicrobial resistance profile displayed. However, those strains carrying the stx(2) gene variant alone or in combination with other virulence factors (stx(1), ehxA or saa gene) were susceptible to most of the tested antibiotics.


Asunto(s)
Farmacorresistencia Bacteriana , Proteínas de Escherichia coli/genética , Escherichia coli/clasificación , Escherichia coli/efectos de los fármacos , Filogenia , Aguas del Alcantarillado/microbiología , Toxina Shiga II/genética , Factores de Virulencia/genética , Animales , Antibacterianos/farmacología , Técnicas de Tipificación Bacteriana , Escherichia coli/genética , Escherichia coli/aislamiento & purificación , Genotipo , Humanos , Pruebas de Sensibilidad Microbiana , Reacción en Cadena de la Polimerasa/métodos , Serotipificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...